

NOVARTIS AG
Form F-6EF
September 05, 2006

As filed with the U.S. Securities and Exchange Commission on September 5, 2006

Registration No. 333-

**SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM F-6

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
For Depository Shares Evidenced by American Depositary Receipts**

NOVARTIS AG

(Exact name of issuer of deposited securities as specified in its charter)

Novartis Inc.

(Translation of issuer's name into English)

Switzerland

(Jurisdiction of incorporation or organization of issuer)

JPMORGAN CHASE BANK, N.A.

(Exact name of depository as specified in its charter)

4 New York Plaza, New York, NY 10004

Telephone (212) 623-0636

(Address, including zip code, and telephone number, including area code, of depository's principal executive offices)

Corporation Service Company
2711 Centerville Road, Suite 400
Wilmington, Delaware 19808
1-800-927-9800

(Address, including zip code, and telephone number, including area code, of agent for service)

Copy to:

Scott A. Ziegler, Esq.

Ziegler, Ziegler & Associates LLP

570 Lexington Avenue, 44th Floor

New York, New York 10022

(212) 319-7600

It is proposed that this filing become effective under Rule 466

immediately upon filing

on (Date) at (Time)

If a separate registration statement has been filed to register the deposited shares, check the following box.

CALCULATION OF REGISTRATION FEE

Title of each class of Securities to be registered	Amount to be registered	Proposed maximum aggregate price per unit (1)	Proposed maximum aggregate offering price (2)	Amount of registration fee
American Depositary Shares evidenced by American Depositary Receipts, each American Depositary Share representing one registered share of Novartis AG	250,000,000 American Depositary Shares	\$0.05	\$12,500,000	\$1337.50

(1) Each Unit represents one American Depositary Share.

(2) Estimated solely for the purpose of calculating the registration fee. Pursuant to Rule 457(k), such estimate is computed on the basis of the maximum aggregate fees or charges to be imposed in connection with the issuance of American Depositary Receipts evidencing American Depositary Shares.

**PART I
INFORMATION REQUIRED IN PROSPECTUS**

The Prospectus consists of the proposed form of American Depositary Receipt (“ADR” or “American Depositary Receipt”) included as Exhibit (a)(5) to this Registration Statement, which is incorporated herein by reference.

CROSS REFERENCE SHEET

Item 1. DESCRIPTION OF SECURITIES TO BE REGISTERED

Item Number and Caption		Location in Form of American Depositary Receipt Filed Herewith as Prospectus
(1)	Name and address of Depositary	Introductory paragraph
(2)	Title of American Depositary Receipts and identity of deposited securities	Face of American Depositary Receipt, top center
	Terms of Deposit:	
(i)	Amount of deposited securities represented by one unit of American Depositary Shares	Face of American Depositary Receipt, upper right corner
(ii)	Procedure for voting, if any, the deposited securities	Paragraphs (13)
(iii)	Collection and distribution of dividends	Paragraphs (4), (5), (7) and (10)
(iv)	Transmission of notices, reports and proxy soliciting material	Paragraphs (3), (8) and (12)
(v)	Sale or exercise of rights	Paragraphs (4), (5) and (10)
(vi)	Deposit or sale of securities resulting from dividends, splits or plans of reorganization	Paragraphs (4), (5), (10) and (14)
(vii)	Amendment, extension or termination of the Deposit Agreement	Paragraphs (17) and (18)
(viii)	Rights of holders of receipts to inspect the transfer books of the Depositary and the list of Holders of receipts	Paragraph (3)
(ix)	Restrictions upon the right to deposit or withdraw the underlying securities	Paragraphs (1), (2), (4) and (5)
(x)	Limitation upon the liability of the Depositary	Paragraph (15)
(3)	Fees and Charges	Paragraph (7)

Item 2. AVAILABLE INFORMATION

Item Number and Caption	Location in Form of American Depository Receipt Filed Herewith as Prospectus
(b) Statement that Novartis AG is subject to the periodic reporting requirements of the Securities Exchange Act of 1934 and, accordingly, files certain reports with the Commission -- and that such reports can be inspected by holders of American Depository Receipts and copied at public reference facilities maintained by the Commission in Washington, D.C.	Paragraph (8)

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 3. EXHIBITS

- (a)(1) **Form of Deposit Agreement.** Amended and Restated Deposit Agreement dated as of May 11, 2000 among Novartis AG, JPMorgan Chase Bank (fka Morgan Guaranty Trust Company of New York), as depository (the "Depository"), and all holders from time to time of ADRs issued thereunder (the "Deposit Agreement"). Previously filed as an Exhibit to Registration Statement No. 333-11758 which is incorporated herein by reference.
- (a)(2) **Form of Amendments to Deposit Agreement.** Previously filed as Exhibits to Registration Statement No. 333-11758 and/or 333-13446 each of which are incorporated herein by reference.
- (a)(3) **Letter Agreement dated October 27, 2004 between Novartis AG and JPMorgan Chase Bank, as depository.** Previously filed as an Exhibit to Annual Report on Form 20-F for the year ended December 31, 2004 which is incorporated herein by reference.
- (a)(4) **Letter Agreement dated September 12, 2005 between Novartis AG and JPMorgan Chase Bank, as depository.** Previously filed as an Exhibit to Annual Report on Form 20-F for the year ended December 31, 2005 which is incorporated herein by reference.

(a)(5) **Form of ADR.** Filed herewith as Exhibit (a)(5).

- (b) **Any other agreement to which the Depository is a party relating to the issuance of the American Depositary Shares registered hereunder or the custody of the deposited securities represented thereby.** Not Applicable.
- (c) **Every material contract relating to the deposited securities between the Depository and the issuer of the deposited securities in effect at any time within the last three years.** Not Applicable.
- (d) **Opinion of Ziegler, Ziegler & Associates LLP, counsel to the Depository, as to the legality of the securities being registered.** Filed herewith as Exhibit (d).

(e) **Certification under Rule 466.** Filed herewith as Exhibit (e).

(f) **Power of Attorney.** Included as part of the signature pages hereto.

Item 4. UNDERTAKINGS

- (a) The Depository hereby undertakes to make available at the principal office of the Depository in the United States, for inspection by holders of the American Depositary Receipts, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depository as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer.
- (b) If the amounts of fees charged are not disclosed in the prospectus, the Depository undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depository undertakes to notify each registered holder of an American Depositary Receipt thirty days before any change in the fee schedule.

SIGNATURE

Pursuant to the requirements of the Securities Act of 1933, as amended, JPMorgan Chase Bank, N.A., on behalf of the legal entity created by the Deposit Agreement, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in The City of New York, State of New York, on September 5, 2006.

Legal entity created by the form of Deposit Agreement for the issuance of ADRs evidencing American Depositary Shares

By: JPMORGAN CHASE BANK, N.A., as
Depositary

By: /s/Joseph M. Leinhauser
Name: Joseph M. Leinhauser
Title: Vice President

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, Novartis AG certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, on September 5, 2006.

NOVARTIS AG

By: /s/Dr. Raymond Breu
Name: Dr. Raymond Breu
Title: Chief Financial Officer

By: /s/Dr. Urs Baerlocher
Name: Dr. Urs Baerlocher
Title: Head of Legal and Tax Affairs

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints two of Daniel Vasella, Raymond Breu and Urs Baerlocher , as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including pre-effective and post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities indicated as of September 5, 2006.

<u>Name</u>	<u>Title</u>
/s/Dr. Daniel Vasella . Dr. Daniel Vasella	Chairman and Chief Executive Officer
/s/Hans-Jörg Rudloff . Hans-Jörg Rudloff	Vice-Chairman
/s/Ulrich Lehner, Ph.D . Ulrich Lehner, Ph. D.	Vice-Chairman

/s/Dr. Raymond Breu . Dr. Raymond Breu	Chief Financial Officer
/s/Dr. h.c. Birgit Breuel . Dr. h.c. Birgit Breuel	Director
/s/Prof. Dr. Peter Burckhardt. Prof. Dr. Peter Burckhardt	Director
/s/Srikant Datar, Ph.D. . Srikant Datar, Ph.D.	Director
/s/William George . William George	Director
/s/Alexandre F. Jetzer . Alexandre F. Jetzer	Director
/s/Pierre Landolt . Pierre Landolt	Director
/s/Dr. Andreas von Planta . Dr. Andreas von Planta.	Director
/s/Dr.-Ing. Wendelin Wiedeking Dr.-Ing. Wendelin Wiedeking	Director
/s/Prof. Dr. Rolf Zinkernagel Prof. Dr. Rolf Zinkernagel	Director
/s/Paulo Costa . Paulo Costa	Authorized Representative in the United States

INDEX TO EXHIBITS

Exhibit Number	Sequentially Numbered Page
(a)(5) Form of ADR.	
(d) Opinion of Ziegler, Ziegler & Associates LLP, counsel to the Depository, as to the legality of the securities to be registered.	
(e) Rule 466 Certification	